{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-016589","form_type":"8-K","ticker":"OLMA","cik":"0001750284","company_name":"Olema Pharmaceuticals, Inc.","filed_at":"2023-10-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.307714+00:00","generated_at":"2026-06-09T16:56:18.935472+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Olema reports Phase 2 palazestrant results: median PFS 4.6 mo in all patients; 7.2 mo in 2nd/3rd-line subset","bullets":["Palazestrant (OP-1250) median PFS of 4.6 months (CBR 40%) in 86 heavily pretreated metastatic ER+/HER2- breast cancer patients.","In ESR1-mutant patients (48% of ctDNA-assessed), median PFS 5.6 months, CBR 52%; in 2nd/3rd-line subset PFS 7.3 mo, CBR 59%.","Safety: well-tolerated at 120 mg; Grade 4 neutropenia in 6 patients (all prior CDK4/6i), managed with dose reduction/discontinuation.","Company plans to initiate OPERA-01, a Phase 3 pivotal monotherapy trial in 2nd/3rd-line metastatic breast cancer.","Results presented at ESMO 2023; Olema hosted investor call on Oct 23, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-016589","json":"https://secwatch.observer/filing/0001558370-23-016589.json","markdown":"https://secwatch.observer/filing/0001558370-23-016589.md","text":"https://secwatch.observer/filing/0001558370-23-016589.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1750284/000155837023016589/0001558370-23-016589-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1750284/000155837023016589/olma-20231022x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T16:56:18.935472+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}